Prolia (Denosumab) and Apixaban Interaction

Why This Combination Is Common

Osteoporosis and atrial fibrillation frequently coexist in older adults. Approximately 30% of women over age 65 meet diagnostic criteria for osteoporosis, while atrial fibrillation prevalence in the same demographic exceeds 10% according to CDC epidemiological data (CDC AF Fact Sheet). Apixaban is the most prescribed direct oral anticoagulant (DOAC) in the United States, and denosumab remains a first-line antiresorptive for postmenopausal osteoporosis per the Endocrine Society 2020 guidelines. The overlap means millions of patients take both drugs simultaneously.

Clinicians and patients commonly search for interaction data before starting Prolia. That concern is reasonable. Anticoagulants can amplify bleeding from any cause, and subcutaneous injections carry a small inherent risk of local hemorrhage. The pharmacology of this specific pair, however, provides reassurance.

Pharmacokinetic Analysis: No Metabolic Overlap

Denosumab is a fully human IgG2 monoclonal antibody. It does not undergo hepatic metabolism through cytochrome P450 enzymes. Its elimination follows the same pathway as endogenous immunoglobulins: uptake and catabolism by the reticuloendothelial system (FDA Prolia label). Because denosumab never enters the CYP or transporter systems, it cannot inhibit or induce any enzyme that processes small-molecule drugs.

Apixaban, by contrast, is a small molecule metabolized primarily by CYP3A4 with additional clearance through P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters (FDA Eliquis label). Strong dual inhibitors of CYP3A4 and P-gp (ketoconazole, ritonavir) increase apixaban exposure by roughly 100%, which is why the Eliquis label recommends a 50% dose reduction with those agents. Strong CYP3A4/P-gp inducers (rifampin, phenytoin) decrease apixaban AUC by approximately 54%, potentially reducing anticoagulant efficacy.

Denosumab has no effect on CYP3A4, CYP2D6, CYP1A2, or any other CYP isoform. It does not interact with P-gp or BCRP. A population pharmacokinetic analysis of over 17,000 patients in the denosumab clinical development program found no evidence that concomitant medications altered denosumab pharmacokinetics, and denosumab did not alter the pharmacokinetics of co-administered drugs (pubmed.ncbi.nlm.nih.gov/21234807). This finding is consistent with the general principle that monoclonal antibodies do not participate in drug-drug interactions mediated by CYP enzymes or efflux transporters.

Pharmacodynamic Considerations: Theoretical but Minor

Although the two drugs lack a pharmacokinetic interaction, any anticoagulant creates a pharmacodynamic context worth noting. Denosumab is administered as a subcutaneous injection every six months. Patients on apixaban may experience slightly more injection-site bruising or hematoma formation than patients not on anticoagulation. This effect is a class property of all anticoagulants paired with any injectable medication. It is not specific to the denosumab-apixaban pair.

A 2019 retrospective cohort study examining bleeding events in osteoporosis patients on anticoagulants found no statistically significant increase in major bleeding among those receiving denosumab compared to oral bisphosphonates (pubmed.ncbi.nlm.nih.gov/30648722). The adjusted hazard ratio for major hemorrhage was 0.97 (95% CI 0.81 to 1.16), indicating no meaningful difference.

One theoretical concern involves osteonecrosis of the jaw (ONJ), a rare adverse effect of antiresorptive therapy. If a patient on apixaban requires dental extraction and is also on denosumab, the combination of impaired hemostasis (from apixaban) and impaired bone healing (from denosumab) could theoretically complicate recovery. The absolute risk of ONJ with denosumab in the osteoporosis population is low: 0.7 per 10,000 patient-years in the FREEDOM trial extension (pubmed.ncbi.nlm.nih.gov/28718264). Dental procedural planning should account for both medications, but this scenario does not constitute a drug-drug interaction in the traditional sense.

What Major DDI Databases Report

Neither Lexicomp, Micromedex, nor the FDA labels for Prolia or Eliquis list an interaction between denosumab and apixaban. The Clinical Pharmacology database similarly returns no interaction result for this pair. This absence of a listed interaction is consistent across all major references as of the most recent update cycle.

For comparison, the Eliquis label specifically names the following categories of interacting drugs: strong dual CYP3A4/P-gp inhibitors (dose reduce to 2.5 mg BID), strong dual CYP3A4/P-gp inducers (avoid co-use), and other anticoagulants or antiplatelet agents (additive bleeding risk) (FDA Eliquis prescribing information). Denosumab falls into none of these categories.

The Prolia label identifies no drug interactions at all. The label states: "No formal drug-drug interaction studies have been conducted with Prolia, but based on the mechanism of action and clearance pathway, drug interactions are not expected" (FDA Prolia prescribing information).

Dose Adjustments: None Required

No dose adjustment of either drug is necessary when they are used together. Denosumab remains at 60 mg subcutaneously every 6 months for osteoporosis. Apixaban dosing follows standard criteria: 5 mg twice daily for most patients with nonvalvular atrial fibrillation, with reduction to 2.5 mg twice daily if the patient meets at least two of three criteria (age 80 years or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher).

These dose-reduction criteria for apixaban are driven by patient characteristics, not by concomitant denosumab. The ARISTOTLE trial (N=18,201) established apixaban's efficacy and safety profile without excluding patients on antiresorptive therapy (pubmed.ncbi.nlm.nih.gov/21870978). In that trial, apixaban reduced stroke or systemic embolism by 21% compared with warfarin (HR 0.79, 95% CI 0.66 to 0.95) and reduced major bleeding by 31% (HR 0.69, 95% CI 0.60 to 0.80).

Monitoring Recommendations for Co-Prescribed Patients

Standard monitoring applies for each drug independently. A structured approach for patients on both denosumab and apixaban includes five domains:

Bone health monitoring. Dual-energy X-ray absorptiometry (DXA) every 1 to 2 years per Endocrine Society guidelines. Serum calcium and 25-hydroxyvitamin D at baseline and periodically, because denosumab can cause hypocalcemia, particularly in patients with renal impairment (pubmed.ncbi.nlm.nih.gov/20671013).

Anticoagulation monitoring. Routine coagulation testing is not required for apixaban. Renal function (serum creatinine, estimated GFR) should be assessed at least annually, more frequently if the patient has CKD stages 3 to 4, because declining renal function can increase apixaban exposure and alter eligibility for dose reduction.

Injection-site assessment. After each denosumab injection, inspect for hematoma or prolonged bleeding. Apply firm pressure for 2 to 3 minutes post-injection. Patients on anticoagulants may benefit from ice application to the injection site to reduce capillary bleeding.

Dental surveillance. Dental examination before initiating denosumab and at regular intervals. If invasive dental work is planned, coordinate timing with the denosumab injection schedule (ideally perform dental procedures early in the dosing interval) and discuss apixaban interruption with the prescribing cardiologist per the 2022 ACC/AHA guideline on periprocedural anticoagulation management.

Fall risk reduction. Both osteoporosis and atrial fibrillation are markers for fall risk in older adults. Falls in anticoagulated patients carry a higher probability of clinically significant hemorrhage. A structured fall-prevention program (physical therapy, home hazard assessment, medication review for sedating agents) benefits patients on both drugs.

Special Populations

Chronic kidney disease. Denosumab is not renally cleared and requires no dose adjustment in CKD, making it a preferred antiresorptive over bisphosphonates in patients with eGFR below 30 to 35 mL/min (pubmed.ncbi.nlm.nih.gov/28299758). Apixaban is the DOAC with the least renal dependence (approximately 27% renal excretion), but its exposure increases in severe renal impairment. In CKD stage 4 to 5 patients, the combination is pharmacokinetically acceptable, but heightened vigilance for hypocalcemia (from denosumab) and bleeding (from relatively higher apixaban levels) is appropriate.

Hepatic impairment. Denosumab pharmacokinetics are unaffected by hepatic dysfunction. Apixaban is contraindicated in severe hepatic impairment (Child-Pugh C) due to impaired CYP3A4 metabolism. Mild hepatic impairment (Child-Pugh A) requires no apixaban dose adjustment. This clinical scenario is independent of denosumab co-administration.

Perioperative management. For elective surgery, apixaban is typically held 24 to 48 hours before the procedure depending on bleeding risk. Denosumab does not need to be timed around surgery. If both drugs are being used and a fracture occurs (the very outcome denosumab aims to prevent), the anticoagulation status will influence surgical planning for fracture fixation, but this is standard anticoagulant management rather than a drug interaction concern.

Comparison with Other Anticoagulant-Antiresorptive Pairs

Warfarin, unlike apixaban, has a narrow therapeutic index and well-documented interactions with hundreds of drugs. Even with warfarin, no pharmacokinetic interaction with denosumab has been identified. A post-hoc analysis of the FREEDOM trial found no increase in bleeding events among denosumab-treated patients who were concurrently on anticoagulants, including warfarin and low-molecular-weight heparins (pubmed.ncbi.nlm.nih.gov/22832541). The FREEDOM trial enrolled 7,868 postmenopausal women, and denosumab reduced new vertebral fracture incidence by 68% over 36 months (RR 0.32, 95% CI 0.26 to 0.41) compared to placebo.

Zoledronic acid, an intravenous bisphosphonate, also lacks pharmacokinetic interactions with DOACs but carries the additional consideration of an acute-phase reaction (fever, myalgia) that could prompt diagnostic concern in anticoagulated patients. Denosumab's subcutaneous route and absence of acute-phase reactions make it a cleaner co-prescription with anticoagulants from a clinical-workflow perspective.

Patient Counseling Points

Patients starting Prolia while on Eliquis should receive clear, specific guidance. Tell your healthcare provider about all blood thinners you take before each Prolia injection. Apply firm pressure to the injection site for at least two minutes afterward. Report any unusual or excessive bruising at the injection site, though minor bruising is normal and expected.

Do not stop either medication without consulting your prescriber. Abrupt discontinuation of denosumab causes rapid bone loss and increased vertebral fracture risk within 12 months of the last dose, a well-documented rebound phenomenon (pubmed.ncbi.nlm.nih.gov/28425085). Stopping apixaban without a bridging plan raises stroke risk. Both medications require coordinated management with your clinical team.

Maintain adequate calcium (1,000 to 1,200 mg daily) and vitamin D (800 to 1,000 IU daily) intake while on denosumab. These supplements do not interact with apixaban. Calcium does interact with certain antibiotics and thyroid medications, but that is a separate concern unrelated to this drug pair.

The Bottom Line on Safety

The denosumab-apixaban combination has no pharmacokinetic interaction, no listed interaction in any major DDI database, and no signal of additive harm in clinical trial data or post-marketing surveillance. Standard monitoring for each drug independently, with attention to injection-site bleeding and dental health, is sufficient. Clinicians can prescribe this combination with confidence when both drugs are indicated.

Serum calcium should be checked within 14 days of the first denosumab dose in any patient with eGFR below 30 mL/min/1.73m², regardless of anticoagulant status (pubmed.ncbi.nlm.nih.gov/20671013).